NCT00260234View on ClinicalTrials.gov

Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

Allogeneic Cultured Islet Cells (human); Encapsulated

Trial Locations (2)

78229

CHRISTUS Santa Rosa Transplant Institute, San Antonio

Diabetes & Glandular Disease Research Associates, P.A., San Antonio

Sponsors

Lead Sponsor

Novocell
All Listed Sponsors
collaborator

Diabetes & Glandular Disease Research Associates, P.A., San Antonio, TX

UNKNOWN

collaborator

CHRISTUS Health

OTHER

lead

Novocell

INDUSTRY